Literature DB >> 24061764

A comparative study on the use of tamsulosin versus alfuzosin in spontaneous micturition recovery after transurethral catheter removal in patients with benign prostatic growth.

Miguel Maldonado-Ávila1, Hugo A Manzanilla-García, José A Sierra-Ramírez, José D Carrillo-Ruiz, Juan C González-Valle, Emanuelle Rosas-Nava, José Guzman-Esquivel, Isaac R Labra-Salgado.   

Abstract

PURPOSE: To compare the efficacy and safety of tamsulosin and alfuzosin in patients with acute urinary retention (AUR) secondary to benign prostatic hyperplasia (BPH).
METHODS: Ninety men with AUR due to BPH underwent urinary catheterization and were randomly assigned to treatment groups with tamsulosin 0.4 mg (37 patients), alfuzosin 10 mg (34 patients), and placebo (19 patients). After 4 days of the drug treatment, the catheters were removed, and the patients underwent trial without catheter (TWOC). A TWOC was considered successful if the patient had a voided volume >100 ml and post-void residual urine <200 ml.
RESULTS: TWOC was successful in 16 patients (43.2 %) in the tamsulosin group, 12 patients (35.2 %) in the alfuzosin group, and 5 patients (26.3 %) in the placebo group. Logistic regression analysis showed that both drugs were equally effective and that the type of alpha-blocker was not a predictive factor for TWOC success (OR 1.137, 95 % CI 0.639-2.022) (p = 0.662).
CONCLUSION: Even though there were no statistically significant differences when comparing the three groups, tamsulosin showed a tendency to be more effective in a successful catheter removal. The lack of objective criteria in the definition of successful micturition leads us to believe that the effectiveness of both drugs reported in the literature is overestimated.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24061764     DOI: 10.1007/s11255-013-0515-y

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  24 in total

1.  Natural history of prostatism: risk factors for acute urinary retention.

Authors:  S J Jacobsen; D J Jacobson; C J Girman; R O Roberts; T Rhodes; H A Guess; M M Lieber
Journal:  J Urol       Date:  1997-08       Impact factor: 7.450

2.  Trial without catheter following acute retention of urine.

Authors:  M Taube; H Gajraj
Journal:  Br J Urol       Date:  1989-02

3.  In vitro characterization of the alpha-adrenoceptors in human prostate.

Authors:  J P Hieble; M Caine; E Zalaznik
Journal:  Eur J Pharmacol       Date:  1985-01-02       Impact factor: 4.432

Review 4.  Alpha 1-adrenoceptor classification: sharpening Occam's razor.

Authors:  A P Ford; T J Williams; D R Blue; D E Clarke
Journal:  Trends Pharmacol Sci       Date:  1994-06       Impact factor: 14.819

5.  Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study.

Authors:  S A McNeill; T B Hargreave; Claus G Roehrborn
Journal:  Urology       Date:  2005-01       Impact factor: 2.649

6.  Acute retention of urine: is trial without catheter justified?

Authors:  K J Hastie; A J Dickinson; R Ahmad; C U Moisey
Journal:  J R Coll Surg Edinb       Date:  1990-08

Review 7.  Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia.

Authors:  M I Wilde; A Fitton; D McTavish
Journal:  Drugs       Date:  1993-03       Impact factor: 9.546

8.  Alfuzosin 10 mg once daily increases the chances of successful trial without catheter after acute urinary retention secondary to benign prostate hyperplasia.

Authors:  H Y Tiong; M J B Tibung; M Macalalag; M K Li; D Consigliere
Journal:  Urol Int       Date:  2009-07-27       Impact factor: 2.089

Review 9.  The Reten-World survey of the management of acute urinary retention: preliminary results.

Authors:  Mark Emberton; John M Fitzpatrick
Journal:  BJU Int       Date:  2008-03       Impact factor: 5.588

10.  The management of men with acute urinary retention. National Prostatectomy Audit Steering Group.

Authors:  R Pickard; M Emberton; D E Neal
Journal:  Br J Urol       Date:  1998-05
View more
  6 in total

Review 1.  Systematic review and meta-analysis on management of acute urinary retention.

Authors:  P D Yoon; V Chalasani; H H Woo
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-07-21       Impact factor: 5.554

Review 2.  [Acute urinary retention in men: efficacy of alpha-blockers in catheter removal after urinary retention].

Authors:  S Mühlstädt; M Oelke
Journal:  Urologe A       Date:  2019-06       Impact factor: 0.639

Review 3.  Α₁-blockers in the management of acute urinary retention secondary to benign prostatic hyperplasia: a systematic review and meta-analysis.

Authors:  D Guang-Jun; G Feng-Bin; J Xun-Bo
Journal:  Ir J Med Sci       Date:  2014-03-06       Impact factor: 1.568

4.  Measuring the improvement in health-related quality of life using King's health questionnaire in non-obese and obese patients with lower urinary tract symptoms after alpha-adrenergic medication: a preliminary study.

Authors:  Jae Heon Kim; Hoon Choi; Hwa Yeon Sun; Seung Whan Doo; Jong Hyun Yoon; Won Jae Yang; Byung Wook Yoo; Joyce Mary Kim; Soon-Sun Kwon; Eun Seop Song; Hong Jun Lee; Ik Sung Lim; Yun Seob Song
Journal:  BMC Urol       Date:  2014-08-06       Impact factor: 2.264

5.  Efficacy and Safety of Silodosin and Dutasteride Combination Therapy in Acute Urinary Retention due to Benign Prostatic Hyperplasia: A Single-Arm Prospective Study.

Authors:  Kazuhisa Hagiwara; Takuya Koie; Hiromichi Iwamura; Atsushi Imai; Shingo Hatakeyama; Takahiro Yoneyama; Yasuhiro Hashimoto; Chikara Ohyama
Journal:  Biomed Res Int       Date:  2016-04-18       Impact factor: 3.411

6.  Acotiamide hydrochloride hydrate added to combination treatment with an α-blocker and a cholinergic drug improved the QOL of women with acute urinary retention: case series.

Authors:  Koichi Sugimoto; Takahiro Akiyama; Nobutaka Shimizu; Naoki Matsumura; Mamoru Hashimoto; Takafumi Minami; Kazuhiro Nose; Masahiro Nozawa; Kazuhiro Yoshimura; Hirotsugu Uemura
Journal:  Res Rep Urol       Date:  2017-08-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.